Nataliya Razumilava and Gregory J Gores. Cholangiocarcinoma. Lancet. 2014;383:2168-2179.
 Yao D, Kunam V, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res. 2014;42:3-16.
 Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.
 Razumilava N and Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179.
 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57:69-76.
 Charbel H and Al-Kawas F. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep. 2011;13:182-187.
 Ruzzenente A, Conci S, Valdegamberi A, et al. Role of surgery in the treatment of intrahepatic cholangiocarcinoma. Eur Rev Med Pharmacol Sci.2015;19:2892-2900.
 Huang J, Jiang B, Yang Y, et al. Influencing factors for the prognosis of patients with early-stage intrahepatic cholangiocarcinoma after radical resection. J Clin Hepatol. 2018;34:2157-2163.
 Lim K, Han S,Oh D, et al. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology. 2012;83:57-66.
 Valle J, Wasan H, Palmer D, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-81.
 Liu S, Zhou L and An L. Implementation of comprehensive rehabilitation therapy in postoperative care of patients with cholangiocarcinoma and its impact on patients' quality of life. Exp Ther Med. 2019;17:2703-2707.
 Chen Z, Ma X, Zhao Y, et al. Yinchenhao decoction in the treatment of cholestasis: A systematic review and meta-analysis. J Ethnopharmacol. 2015;168:208-216.
 Jiang S, Hu X and Liu P. Immunomodulation and liver protection of Yinchenhao decoction against concanavalin A-induced chronic liver injury in mice. J Integr Med. 2015;13:262-268.
 Qi J. Clinical Observation on Modified Yinchenhao Decoction Combined with Tegafur GimeracilOteracil Potassium Capsule in the Treatment of Advanced Pancreatic Cancer. Guangming Journal of Chinese Medicine. 2018;33:563-564.
 Song Z, Song H and Song P. Clinical Observation of Modified Yinchenhao Tang Combined with Cisplatin Intraperi-toneal Perfusion for Ascites Hepatoma. Journal of New Chinese Medicine. 2018;50:139-142.
 Li S, Zhang B, Jiang D, et al. Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. BMC Bioinformatics. 2010;11(Suppl 11): S1-S12.
 Ru J, Li P, Wang J,et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminformatics. 2014;6:13.
 Huang L, Xie D, Yu Y, et al. TCMID 2.0: a comprehensive resource for TCM. Nucleic Acids Res. 2018;46:D1117-D1120.
 Kramer C, Podewitz M, Ertl P, et al. Unique macrocycles in the Taiwan traditional Chinese medicine database. Planta Med. 2015;816:459-466.
 Chao W, Lin B.Bioactivities of major constituents isolated from Angelica sinensis (Danggui). Chin Med. 2011;6:29.
 Tao W, Xu X, Wang X, et al.Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol. 2013;145:1-10.
 Li X, Xu X, Wang J, et al. A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment. PLoS One. 2012;7:e43918.
 He F, Wang M, Li K, et al. Efficacy analysis of hepatic arterial infusion in combination with intravenous gemcitabine chemotherapy for advanced intrahepatic cholangiocarcinoma. Chinese Journal of General Surgery. 2018;27:219-224.
 Guo Y, Li J, Mao T, et al. Effect of Combined Prescription of Linggui Zhugan Tang and Yinchenhao Tang on Nrf2/ARE Signaling Pathway in Rats with Non-alcoholic Steatohepatitis. Chinese Journal of Experimental Traditional Medical Formulae. 2017;23:108-113.
 Huang J, Cheung F, Tan H, et al. Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology. Mol Med Rep. 2017;16:4583-4592.
 Reyes-Farias M and Carrasco-Pozo C. The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism. Int J Mol Sci. 2019;20:3177.
 Erdogan S, Turkekul K, Dibirdik I, et al. Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway. Biomed Pharmacother. 2018;107:793-805.
 Senggunprai L, Kukongviriyapan V, Prawan A, et al. Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway. Phytother Res. 2014;28:841-848.
 Qin Y, Cui W, Yang X, et al. Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2016;48:238-245.
 Bin Sayeed MS and Ameen SS. Beta-Sitosterol: A Promising but Orphan Nutraceutical to Fight Against Cancer. Nutr Cancer. 2015;67:1214-1220.
 Manu KA, Shanmugam MK, Ramachandran L, et al. Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer. Cancer Lett.2015;363:28-36.
 Kangsamaksin T, Chaithongyot S, Wootthichairangsan C, et al. Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor-α. PLoS One.2017;12:e0189628.
 Ewald F, Grabinski N, Grottke A, et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. 2013;133:2065-2076.
Tanjak P, Thiantanawat A, Watcharasit P, et al. Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors. Int J Oncol.2018;53:177-188.
 Zheng Y, Zhou C, Yu XX, et al. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin. Cell Death Dis.2018;9:179.
 Hill MA, Alexander WB, Guo B, et al. Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res. 2018;78:4445-4451.
 Peng T, Deng X, Tian F, et al. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma. Int J Oncol.2019;55:657-670.
 Kadonaga J. Perspectives on the RNA polymerase II core promoter. Wiley Interdiscip Rev Dev Biol. 2012;1:40-51.
 Chujan S, Suriyo T and Satayavivad J. Integrative In Silico and In Vitro Transcriptomics Analysis Revealed Gene Expression Changes and Oncogenic Features of Normal Cholangiocytes after Chronic Alcohol Exposure. Int J Mol Sci.2019;20:5987.
 Rather M, Swamy S, Gopinath K, et al. Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. J Biol Chem. 2014;289:968-976.
 Celli A and Que F. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis. 1998;18:177-185.
 Andersen JB. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22:101-113.
 Labib PL, Goodchild G and Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer. 2019;19:185.
 Huang T, Ding X, Xu G, et al. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. Cell Death Dis. 2019;10:602.
 Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2016;379:198-205.
 Jeong S, Tong Y, Sha M, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:17292-17300.
 Jiang B, Ge R, Sun L, et al. Clinical parameters predicting survival duration after hepatectomy for intrahepatic cholangiocarcinoma. Can J Gastroenterol. 2011;25:603-608.
 Chen C, Nelson L, Ávila MA, et al. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells.2019;8:1172.
 Peng R, Zhang PF, Zhang C, et al. Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med.2018;7:796-808.
 Li H, Hu J, Wu S, et al. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget.2016;7:3548-3558.
 Burris HA. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol.2013;71:829-842.
 Polivka J and Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther.2014;142:164-175.
 Duan H, Li B, Zhaung X, et al. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling. Am J PhysiolGastrointestLiver Physiol. 2019;316:G763-G773.
 Chang Y, Yin F, Fan GF, et al. Downregulation of miR-329-3p is associated with worse prognosis in patients withcervical cancer. Eur Rev Med Pharmacol Sci. 2017;21:4045-4049.
 Hu Z, Zheng C, Su H, et al. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma. J Cell Biochem. 2019;120:9964-9978.
Liu Y, Tang ZG, Yang JQ, et al. Low concentration of quercetin antagonizes the invasion and angiogenesis of human glioblastoma U251 cells. Onco Targets Ther. 2017;10:4023-4028.
 Wang Z, Sun W, Sun X, et al. Kaempferol ameliorates Cisplatin induced nephrotoxicity by modulating oxidative stress, inflammation and apoptosis via ERK and NF-κB pathways. AMB Express. 2020;10:58.
 Moon D, Lee K, Choi Y, et al. Beta-sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells. Int Immunopharmacol. 2007;7:1044-1053.
 Yu G, Zhang Y, Ren W, et al. Network pharmacology-based identification of key pharmacological pathways of Yin-Huang-Qing-Fei capsule acting on chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2016;12:85-94.
 Lee W, Lee C, Kim Y, et al. The Methodological Trends of Traditional Herbal Medicine Employing Network Pharmacology. Biomolecules. 2019;9:362.